Primary aldosteronism - careful investigation is essential and rewarding

被引:124
作者
Stowasser, M
Gordon, RD
机构
[1] Univ Queensland, Dept Med, Princess Alexandra Hosp, Hypertens Unit, Brisbane, Qld 4102, Australia
[2] Univ Queensland, Dept Med, Hypertens Unit, Greenslopes Hosp, Brisbane, Qld 4120, Australia
关键词
adrenal venous sampling; aldosterone/renin ratio; diagnosis; hyperaldosteronism; hypertension; primary aldosteronism;
D O I
10.1016/j.mce.2003.10.006
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Once considered rare, primary aldosteronism (PAL) is now regarded as the commonest potentially curable and specifically treatable form of hypertension. At Greenslopes Hospital Hypertension Unit (GHHU), the decision in 1991 to screen all (and not just hypokalemic or resistant) hypertensives by aldosterone/renin ratio (ARR) testing led to a 10-fold increase in detection rate of PAL and four-fold increase in removal rate of aldosterone-producing adenomas (APAs). The GHHU/Princess Alexandra Hospital Hypertension Unit PAL series stands at 977 patients and 250 APAs removed with hypertension cured in 50-60% (remainder improved). Reliable detection requires that interfering medications are withdrawn (or their effects considered) before ARR measurement, and reliable methods (such as fludrocortisone suppression testing) to confirm PAL. Adrenal venous sampling is the only dependable way to differentiate APA from bilateral adrenal hyperplasia. Genetic testing has facilitated detection of alucocorticoid-remediable, familial PAL. Identification of mutations causing the more common familial variety described by GHHU in 1991 should further aid in detection of PAL. (C) 2003 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:33 / 39
页数:7
相关论文
共 49 条
[1]  
BIGLIERI EG, 1991, INTERNAL MED, P2188
[2]   Primary hyperaldosteronism: A missed diagnosis in 'essential hypertensives'? [J].
Brown, MA ;
Cramp, HA ;
Zammit, VC ;
Whitworth, JA .
AUSTRALIAN AND NEW ZEALAND JOURNAL OF MEDICINE, 1996, 26 (04) :533-538
[3]  
Celen O, 1996, ARCH SURG-CHICAGO, V131, P646
[4]  
CONN JW, 1964, JAMA-J AM MED ASSOC, V190, P222
[5]  
Conn JW., 1955, J LAB CLIN MED, V45, P3
[6]  
CONN JW, 1968, HARVEY LECT, V62, P257
[7]   Primary hyperaldosteronism in essential hypertensives:: Prevalence, biochemical profile, and molecular biology [J].
Fardella, CE ;
Mosso, L ;
Gómez-Sánchez, C ;
Cortés, P ;
Soto, J ;
Gómez, L ;
Pinto, M ;
Huete, A ;
Oestreicher, E ;
Foradori, A ;
Montero, J .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2000, 85 (05) :1863-1867
[8]   HIGH-INCIDENCE OF PRIMARY ALDOSTERONISM IN 199 PATIENTS REFERRED WITH HYPERTENSION [J].
GORDON, RD ;
STOWASSER, M ;
TUNNY, TJ ;
KLEMM, SA ;
RUTHERFORD, JC .
CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, 1994, 21 (04) :315-318
[9]   PRIMARY ALDOSTERONISM [J].
GORDON, RD .
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 1995, 18 (07) :495-511
[10]   EVIDENCE THAT PRIMARY ALDOSTERONISM MAY NOT BE UNCOMMON - 12-PERCENT INCIDENCE AMONG ANTIHYPERTENSIVE DRUG TRIAL VOLUNTEERS [J].
GORDON, RD ;
ZIESAK, MD ;
TUNNY, TJ ;
STOWASSER, M ;
KLEMM, SA .
CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, 1993, 20 (05) :296-298